Company news

Cabaletta Bio, Inc. news in 2021

Cabaletta Bio, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

December 13, 2021

Cabaletta Bio to Participate in Upcoming Investor Conferences in November

November 8, 2021

Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer

November 8, 2021

Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

October 31, 2021

Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV

October 31, 2021

Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021

October 14, 2021

Cabaletta Bio to Present at the Chardan 5th Annual Genetic Medicines Conference

September 27, 2021

Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

September 6, 2021

Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV

August 17, 2021

Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

August 4, 2021

Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors

June 27, 2021

Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates

May 2, 2021

Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial

May 2, 2021

Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

March 15, 2021

Decks in 2021